2024-519106-12-00尚未招募2 期
Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with anaplastic lymphoma kinase positive (ALK+) locally advanced Stage III Non Small Cell Lung Cancer (NSCLC): ALNEO trial-GOIRC-01-2020
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica19 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2024年12月2日最近更新:
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 33
- 试验地点
- 19
- 主要终点
- The primary endpoint is m ajor pathologic response (MPR), defined as <=10% residual viable tumor cells histologically detected in the resected primary tumor and all resected lymph nodes after surgery
研究概览
简要总结
To assess the activity as major pathologic response of single agent Alectinib as neoadjuvant treatment in patients with ALK positive potentially resectable locally advanced stage III NSCLC.
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Male or female, aged >= 18 years
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0
- •Ability to swallow oral medications.
- •Adequate haematological function defined by white blood cell (WBC) count ≥ 2.500/mm3 with absolute neutrophil count (ANC) ≥ 1.500/mm3, platelet count ≥ 100.000/mm3 and haemoglobin ≥ 9 g/dL.
- •Adequate hepatic function defined by a total bilirubin ≤ 1.5 x the upper limit of normal (ULN) range (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL), serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST ) ≤ 2.5 x ULN (≤ 5 if liver function test elevations are due to liver metastases).
- •Adequate renal function defined by a serum creatinine ≤ 1.5 x ULN or an estimated creatinine clearance of ≥ 30 mL/minute for patients with creatinine levels above institutional limits (if using the Cockcroft Gault formula).
- •Stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections, or major surgery within 4 weeks before trial inclusion date , and otherwise noted in other inclusion/exclusion criteria
- •Female patients with childbearing potential should be using adequate contraceptive measures and should not be breastfeeding during the study and for 90 days following the last dose of Alectinib . They and must have a negative serum pregnancy test within 7 days prior to the first dose of study drug.
- •Female patients must have evidence of non child bearing potential by fulfilling
- •Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as described in the full protocol for at least 14 days prior to administration of the first dose of study treatment, during t he study, and for 90 days following the last dose of Alectinib.
- •Ability to comply with protocol requirements.
- •Histologically or cytologically confirmed adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology.
- •The patient is able to provide written informed consent. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that the patient may withdraw consent at any time w ithout prejudice to future medical care.
- •Documented ALK positive disease according to an FDA approved and CE marked test.
- •Locally advanced NSCLC in stage III according to the 8th American Joint Committee on Cancer TNM edition, defined potentially resectable (any T with N2 , T4N0 1)
- •Documentation that the patient is a candidate for surgical resection of their lung cancer after multidisciplinary discussion.
- •Patients must be treatment naive for NSCLC and eligible to receive treatment with Alectinib.
- •Measurable disease defined by Response Evaluation Criteria in Solid Tumor s (RECIST) 1.1 criteria with CT scan.
- •Brain magnetic resonance imaging (MRI) or CT scan showing no evidence of metastatic disease.
- •Positron emission tomography (PET) computed tomography (CT) showing radiographic stage III lung cancer (mediastinal staging biopsy is allowed but not required).
排除标准
- •Prior treatment with any systemic anti cancer therapy for locally advanced NSCLC including chemotherapy, biologic therapy, including ALK TKI, immunotherapy or any investigational drug.
- •History of hypersensitivity to active or inactive excipients of Alectinib or drugs with a similar chemical structure or class to Alectinib. This includes, but is not limited to, patients with galactose intolerance, a congenital lactase deficiency or glucos e galactose malabsorption.
- •Administration of strong/potent cytochrome P450 (CYP)3A inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with Alectinib except for oral corticosteroids up to 20 mg of prednisolone equivalent per day.
- •Involvement in the planning and/or conduct of the study (applies to both investigator staff and/or staff at the study site).
- •Judgment by the investigator that the subject should not participate in the study if the subject is unlikely to comply with study procedures, restrictions and requirements.
- •Non resectable stage III and stage IV disease with distant metastases (including malignant pleural effusion) identified on PET CT scan or biopsy.
- •Any concurrent and/or active malignancy that has required treatment within 2 years of the first dose of study drug.
- •Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator’s opinion makes it undesirable for the patient to participate in the trial or which would jeopardize comp liance with the protocol; or known active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV); screening for chronic conditions is not required; patients with chronic hepatitis B virus (HBV) with negative HBV viral load on a ppropriate antiviral therapy will be permitted, if able to continue appropriate antiviral therapy throughout treatment period.
- •Any severe infection, including COVID-19, within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infections.
- •History of organ transplant
- •Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of Alectinib.
- •Any of the following cardiac criteria: Mean resting corrected QT interval (QTc)>470 msec, obtained from one electrocardiogram (ECG) Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250msec, symptomatic bradycardia <45 beats/minute.Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relati ves or any concomitant medication known to prolong the QT interval.
- •Males and females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry.
结局指标
主要结局
The primary endpoint is m ajor pathologic response (MPR), defined as <=10% residual viable tumor cells histologically detected in the resected primary tumor and all resected lymph nodes after surgery
The primary endpoint is m ajor pathologic response (MPR), defined as <=10% residual viable tumor cells histologically detected in the resected primary tumor and all resected lymph nodes after surgery
次要结局
- Pathological complete response - Pathological complete response (pCR) is defined as the absence of residual viable tumor cells in all specimens as evaluated by BIPR after surgery
研究者
SCIENTIFIC STUDY COORDINATOR
Scientific
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
研究点 (19)
Loading locations...
相似试验
进行中（未招募）
不适用
Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERIOEUCTR2010-021062-29-ITOVARTIS FARMA45
进行中（未招募）
不适用
Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERIOtransfusion-dependent patients with TM, DBA or congenital sideroblastic anemia with severe cardiac iron overloadMedDRA version: 13.1Level: LLTClassification code 10065974Term: Chronic iron overloadSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2010-021062-29-GRovartis Pharma Services AG45
进行中（未招募）
不适用
Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERIOEUCTR2010-021062-29-GBovartis Pharma Services AG45
进行中（未招募）
1 期
International multicenter study to test the use of 3 combined targeted therapy drugs for Colorectal cancer (encorafenib, binimetinib and cetuximab) in subjects with mutant Metastatic Colorectal CancerBRAF V600E -mutant Metastatic Colorectal CancerMedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2018-000271-32-GBPierre Fabre Médicament90
已完成
2 期
Phase II, open-label, single arm, multicenter study of encorafenib, binimetinib plus cetuximab in subjects with previously untreated BRAF V600E -mutant Metastatic Colorectal CancerNL-OMON50375Pierre Fabre10